GIDE
28.3.2022 13:02:13 CEST | Business Wire | Press release
Several international digital specialists have praised the EU’s Digital Market Act , but say its primary aim is to foster competition among tech companies while trying to reign in some of the tech giants. They say its primary focus is not protecting the personal information of digital users.
“The Digital Market Act definitely places some constraints on how some of these tech giants can use consumers’ personal data, but in terms of giving them control over their own personal information, it comes up short,” said Dr Paul Twomey, one of the lead authors of a report entitled Empowering Digital Citizens .
The report, culminating two-years of work, was presented at the Global Solutions Summit in Berlin, Germany on 28 March 2022. The annual conference brings together senior government officials with top-level academic researchers, NGO leaders, and international CEOs. It transforms research-based insights into policy recommendations for the Group of Seven (G7) and Group of 20 (G20) inter-governmental forums.
“The buying and selling of personal data is part of a $515 billion (USD) market,” says Professor Dennis J. Snower, the report’s other lead author. “Digital users are simply not a part of this transactional system and in many cases don’t even know that it exists, nor do they know who has their personal information or how it is being used. We want humane market dynamics to apply to all participants in the online economy.”
Under the Empowering Digital Citizens proposal, online users would be given control over who has access to the personally identifiable information they create. They can also, with the help of a representative, set the terms under which their data can be used (according to the law), and in return they need to ensure that their data is accurate and verified by trusted third parties. “Only the illicit drug market and online data aggregators refer to people as users,“ says Twomey. “These proposals transform that model. They empower a world of digital citizens able to reinforce their democratic rights and counter the forces of disinformation.”
Twomey and Snower represent the Global Initiative for Digital Empowerment (GIDE), which is made up of over 70 specialists from around the world, including policy experts, researchers, Internet technical experts, business people, security specialists and others. GIDE is an initiative of THE NEW INSTITUTE. Based in Hamburg, THE NEW INSTITUTE is an institute of advanced studies and a platform to find answers to the most pressing ecological, economic and political challenges of our time.
The two digital researchers say a major problem is that many online users of “free services” are given artificially restricted choices of either revealing large amounts of personal data (by agreeing to the terms and conditions of digital services) or being excluded from the economic and social interactions that define modern life.
The Empowering Digital Citizens initiative will make online and digital consumers part of the economic model that is currently invisible to the average consumer.
Access the report here: Empowering Digital Citizens . Access an FAQ on the initiative here: Q&A on Human-Centered Digital Governance .
Membership of the Global Initiative for Digital Empowerment is on page four of the Empowering Digital Citizens report.
About Dr. Paul Twomey: Dr. Twomey is co-lead of the Global Initiative for Digital Empowerment and Fellow and Initiative Director for Digital Governance at THE NEW INSTITUTE. He is a Fellow and Core Theme Leader for “managing information and technology in the public interest” at the Global Solutions Initiative. Twomey is also a Distinguished Fellow at the Centre for International Governance Innovation and a Commissioner of the Global Commission for Internet Governance. He is the former CEO of ICANN, the global coordination body of the Internet’s addressing system.
About Prof. Dennis J. Snower : Prof. Snower is co-lead of the Global Initiative for Digital Empowerment and is the director for the Socio-Economic Transformation programme at THE NEW INSTITUTE.. He is founder and President of the Global Solutions Initiative; Professor of Macroeconomics and Sustainability at the Hertie School, Berlin; Senior Research Fellow at the Blavatnik School of Government, Oxford; and Non-resident Fellow of Brookings Institution. He is co-lead of this project. He is Research Fellow at the Centre for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
